✦ LIBER ✦

Binding activities of infliximab and etanercept to transmembrane tumor necrosis factor-α

✍ Scribed by Hiroki Mitoma; Takahiko Horiuchi; Hiroshi Tsukamoto

Book ID: 119757614
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 115 KB
Volume: 126
Category: Article
ISSN: 0016-5085
DOI: 10.1053/j.gastro.2004.01.036

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Mechanisms for cytotoxic effects of anti

Mechanisms for cytotoxic effects of anti–tumor necrosis factor agents on transmembrane tumor necrosis factor α–expressing cells: Comparison among infliximab, etanercept, and adalimumab

✍ Hiroki Mitoma; Takahiko Horiuchi; Hiroshi Tsukamoto; Yasuhiro Tamimoto; Yasutaka 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 227 KB 👁 1 views

Life-threatening histoplasmosis complica

Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanercept

✍ Jong-Hoon Lee; Nancy R. Slifman; Sharon K. Gershon; Evelyne T. Edwards; William 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB

## Abstract ## Objective Two tumor necrosis factor α (TNFα) antagonists were recently licensed in the US. Infliximab was licensed in 1998 for the treatment of Crohn's disease (CD), and since 1999, it has been licensed in combination with methotrexate for treatment of rheumatoid arthritis (RA). Eta

Comparisons of affinities, avidities, an

Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor

✍ Zehra Kaymakcalan; Paul Sakorafas; Sahana Bose; Susanne Scesney; Limin Xiong; De 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 356 KB

Leader sequence is required for activity

Leader sequence is required for activity of transmembrane tumor necrosis factor-α

✍ Fang Zheng; Na Liu; Qizheng Chen; Lin Yang; Lili Liu; Ping Xiong; Wei Feng; Xiao 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 591 KB

Tumor necrosis factor and granuloma biol

Tumor necrosis factor and granuloma biology: Explaining the differential infection risk of etanercept and infliximab

✍ Robert S. Wallis; Stefan Ehlers 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 133 KB

Binding of human tumor necrosis factor α

Binding of human tumor necrosis factor α to multimeric complementary peptides

✍ Giorgio Fassina; Giovanni Cassani; Angelo Corti 📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 842 KB